(Q43242497)

17 November 2017

title

Liposome-mediated therapy of neuroblastoma (English)

1 reference

17 November 2017

1

1 reference

17 November 2017

12

1 reference

17 November 2017

14

1 reference

17 November 2017

Alessia Zorzoli

8

0 references

Fabio Pastorino

object named as

Fabio Pastorino

3

0 references

Gabriella Pagnan

object named as

Gabriella Pagnan

15

0 references

Carlo Tacchetti

object named as

Carlo Tacchetti

11

0 references

author name string

Monica Loi

2

1 reference

17 November 2017

Chiara Brignole

4

1 reference

17 November 2017

Danilo Marimpietri

5

1 reference

17 November 2017

Pamela Becherini

6

1 reference

17 November 2017

Irene Caffa

7

1 reference

17 November 2017

Renato Longhi

9

1 reference

17 November 2017

Cristina Gagliani

10

1 reference

17 November 2017

Theresa M Allen

13

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

17 November 2017

published in

Methods in Enzymology

1 reference

17 November 2017

volume

465

1 reference

17 November 2017

page(s)

225-249

1 reference

Monoclonal antibody therapy of cancer

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Perspectives in antisense therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Ligand-targeted therapeutics in anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Drug delivery systems: entering the mainstream

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Steps toward mapping the human vasculature by phage display.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

4-HPR modulates gene expression in ovarian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Neuroblastoma in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

The prognostic value of c-myc oncoprotein levels in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Anti-cancer activity of targeted pro-apoptotic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

1 reference

7 January 2021

The implications of angiogenesis for the biology and therapy of cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Antisense oligonucleotides as therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Colloidal gold--low density lipoprotein conjugates as membrane receptor probes

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Tumour vascularization: sprouting angiogenesis and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Liposomes containing colloidal gold are a useful probe of liposome-cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Tumor regression by targeted gene delivery to the neovasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Brain drug delivery of small molecules using immunoliposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Recent advances in protection against doxorubicin-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Integrins: roles in cancer development and as treatment targets

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Immunotherapeutic uses of CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Aminopeptidase A is a functional target in angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Molecular biology of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

1 reference

7 January 2021

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Development of anti-p185HER2 immunoliposomes for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Targeted delivery of antisense oligonucleotides in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Ligand-targeted liposomal therapies of neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Antisense therapy in oncology: new hope for an old idea?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Application of nanomedical approaches in experimental and clinical oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

In vivo phage display and vascular heterogeneity: implications for targeted medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

The state of the art in antisense research

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

BBC3 mediates fenretinide-induced cell death in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

Mapping tumor vascular diversity by screening phage display libraries

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2809%2965012-6

7 January 2021

10.1016/S0076-6879(09)65012-6

Identifiers

DOI

1 reference

17 November 2017

1 reference